News
Novo puts $285m into monthly GLP-1 based on Ascendis tech
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.